Brazil manufactures its own generic version of Gilead's Viread
This article was originally published in Scrip
A state-owned lab in Brazil, with the help of privately-owned local companies, has begun manufacturing its own generic version of Gilead Sciences's antiretroviral Viread (tenofovir), says the health ministry. The news comes two years after the national intellectual property institute, INPI, rejected Gilead Sciences's patent application for Viread.
You may also be interested in...
Brazil could soon be manufacturing its own generic version of Gilead’s Sovaldi if opposition to the company’s patent application is upheld by the patent office.
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.